Can-Fite BioPharma, Ltd. to Present at the LD Micro Invitational XIV

Rhea-AI Summary

Can-Fite BioPharma, (CANF) to present at The 14th Annual LD Micro Invitational in New York. CEO Motti Farbstein to lead the presentation on April 9th, 2024.

Ramat Gan, Israel--(Newsfile Corp. - April 1, 2024) - Can-Fite BioPharma, Ltd. (NYSE American: CANF) announced today that it will be presenting at The 14th Annual LD Micro Invitational at the Sofitel New York on April 8th-9th, 2024. The event is expected to feature 80 companies presenting in half-hour increments, as well as private 1:1 meetings.

Can-Fite BioPharma, Ltd. is scheduled to present on April 9th at 4:30 PM ET. Motti Farbstein, CEO, will be leading the presentation.

We invite interested parties to register to watch the presentation virtually here.

About Can-Fite BioPharma, Ltd.

Can-Fite BioPharma Ltd. (NYSE American: CANF) (TASE: CANF) is an advanced clinical stage drug development Company with a platform technology that is designed to address multi-billion dollar markets in the treatment of cancer, liver, and inflammatory disease. The Company’s lead drug candidate, Piclidenoson recently reported topline results in a Phase III trial for psoriasis and is expected to commence a pivotal Phase III. Can-Fite’s cancer and liver drug, Namodenoson, is being evaluated in a Phase IIb trial for the treatment of steatotic liver disease (SLD), a Phase III pivotal trial for hepatocellular carcinoma (HCC), and the Company is planning a Phase IIa study in pancreatic cancer. Namodenoson has been granted Orphan Drug Designation in the U.S. and Europe and Fast Track Designation as a second line treatment for HCC by the U.S. Food and Drug Administration. Namodenoson has also shown proof of concept to potentially treat other cancers including colon, prostate, and melanoma. CF602, the Company’s third drug candidate, has shown efficacy in the treatment of erectile dysfunction. These drugs have an excellent safety profile with experience in over 1,600 patients in clinical studies to date. For more information please visit: www.can-fite.com.

About LD Micro

LD Micro, a wholly owned subsidiary of Freedom US Markets, was founded in 2006 with the sole purpose of being an independent resource in the micro-cap space. Whether it is the Index, comprehensive data, or hosting the most significant events annually, LD's sole mission is to serve as an invaluable asset for all those interested in finding the next generation of great companies. For more information on LD Micro, visit www.ldmicro.com.

Please reach out to the company representative below or Dean Summers (dean@ldmicro.com) to register for the event and schedule a meeting with the company.

To learn more about Freedom US Markets, visit www.freedomusmkts.com.

For further information on Can-Fite BioPharma, Ltd.:

Motti Farbstein
CEO
+972528998671
motti@canfite.co.il
https://www.canfite.com/

When is Can-Fite BioPharma, (CANF) presenting at The 14th Annual LD Micro Invitational?

Can-Fite BioPharma, (CANF) is scheduled to present at The 14th Annual LD Micro Invitational on April 9th, 2024.

Who will be leading the presentation at The 14th Annual LD Micro Invitational for Can-Fite BioPharma, (CANF)?

CEO Motti Farbstein will be leading the presentation for Can-Fite BioPharma, (CANF) at The 14th Annual LD Micro Invitational.

Where will The 14th Annual LD Micro Invitational take place for Can-Fite BioPharma, (CANF)?

The 14th Annual LD Micro Invitational will take place at the Sofitel New York.

How can interested parties watch the presentation by Can-Fite BioPharma, (CANF) at The 14th Annual LD Micro Invitational?

Interested parties can register to watch the presentation virtually on the provided link.